Okafor Chigozie G, Eleje George U, Adinma Joseph I, Ikechebelu Joseph I, Umeh Eric O, Okafor Chisolum O, Ugwu Emmanuel O, Ugboaja Joseph O, Nwosu Betrand O, Ezeama Chukwuemeka O, Udigwe Gerald O, Okoro Chukwuemeka C, Egeonu Richard O, Ezema Evaristus C, Umeononihu Osita S, Okpala Boniface C, Okafor Chidinma C, Ofojebe Chukwuemeka J, Ilika Chito P, Oguejiofor Charlotte B, Ogabido Chukwudi A, Umeokafor Chijioke C, James John E, Obiagwu Hillary I, Okafor Lazarus U, Obidike Afam B, Okam Princeston C, Okeke Kenneth N, Inya Anselem O, Njoku Tobechi K, Eleje Lydia I
Department of Obstetrics and Gynaecology, Nnamdi Azikiwe University Teaching Hospital Nnewi, Nnewi, Anambra State, Nigeria.
Effective Care Research Unit, Department of Obstetrics and Gynaecology, Nnamdi Azikiwe University, Nnewi Campus, Awka, Nigeria.
SAGE Open Med. 2023 Mar 11;11:20503121231158220. doi: 10.1177/20503121231158220. eCollection 2023.
To compare Premaquick biomarkers (combined insulin-like growth-factor binding protein 1 and interleukin-6) and cervical length measurement via transvaginal ultrasound for pre-induction cervical evaluation at term among pregnant women.
A randomized clinical trial of consenting pregnant women at the Nnamdi Azikiwe University Teaching Hospital, Nnewi, Nigeria. The women were randomized equally into Premaquick group ( = 36) and transvaginal ultrasound group ( = 36). The cervix was adjudged 'ripe' if the Premaquick test was positive or if the trans-vaginal measured cervical length was less than 28 mm. The primary outcome measures were the proportions of women who needed prostaglandin analogue for cervical ripening and the proportion that achieved vaginal delivery after induction of labour. The trial was registered in Pan African clinical trial registry (PACTR) registry with approval number PACTR202001579275333.
The baseline characteristics were similar between the two groups ( > 0.05). There was no statistically significant difference between the two groups in terms of proportion of women that required prostaglandins for pre-induction cervical ripening (41.7 versus 47.2%, = 0.427), vaginal delivery (77.8 versus 80.6%, = 0.783), mean induction to delivery interval (22.9 ± 2.81 h versus 24.04 ± 3.20 h, = 0.211), caesarean delivery (22.2 versus 19.4%, = 0.783), proportion of neonate with birth asphyxia (8.30 versus 8.30%, = 1.00) and proportion of neonate admitted into special care baby unit (16.7 versus 13.9%, = 0.872). Subgroup analysis of participants with 'ripe' cervix at initial pre-induction assessment showed that the mean induction to active phase of labour interval and mean induction to delivery interval were significantly shorter in Premaquick than transvaginal ultrasound group.
Pre-induction cervical assessment at term with either Premaquick biomarkers or transvaginal ultrasound for cervical length is effective, objective and safe with similar and comparable outcome. However, when compared with women with positive transvaginal ultrasound at initial assessment, women with positive Premaquick test at initial assessment showed a significantly shorter duration of onset of active phase of labour and delivery of baby following induction of labour.
比较Premaquick生物标志物(胰岛素样生长因子结合蛋白1和白细胞介素-6联合检测)和经阴道超声测量宫颈长度在足月孕妇引产术前宫颈评估中的应用效果。
在尼日利亚纽维的纳姆迪·阿齐克韦大学教学医院对自愿参与的孕妇进行一项随机临床试验。将这些孕妇平均随机分为Premaquick组(n = 36)和经阴道超声组(n = 36)。如果Premaquick检测呈阳性或经阴道测量的宫颈长度小于28mm,则判定宫颈“成熟”。主要结局指标为引产时需要使用前列腺素类似物促进宫颈成熟的女性比例以及引产术后实现阴道分娩的比例。该试验已在泛非临床试验注册中心(PACTR)注册,批准号为PACTR202001579275333。
两组的基线特征相似(P>0.05)。两组在引产术前需要使用前列腺素促进宫颈成熟的女性比例(41.7%对47.2%,P = 0.427)、阴道分娩比例(77.8%对80.6%,P = 0.783)、平均引产至分娩间隔时间(22.9±2.81小时对24.04±3.20小时,P = 0.211)、剖宫产比例(22.2%对19.4%,P = 0.783)、新生儿窒息比例(8.30%对8.30%,P = 1.00)以及入住特殊护理婴儿病房的新生儿比例(16.7%对13.9%,P = 0.872)方面均无统计学显著差异。对引产术前初始评估宫颈“成熟”的参与者进行亚组分析显示,Premaquick组的平均引产至产程活跃期间隔时间和平均引产至分娩间隔时间明显短于经阴道超声组。
使用Premaquick生物标志物或经阴道超声测量宫颈长度进行足月引产术前宫颈评估是有效、客观且安全的,结局相似且具有可比性。然而,与初始评估经阴道超声阳性的女性相比,初始评估Premaquick检测阳性的女性在引产术后产程活跃期开始时间和分娩时间明显更短。